

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Tactic Pharma LLC		2. Issuer Name and Ticker or Trading Symbol Monopar Therapeutics [MNPR]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ Director <input checked="" type="checkbox"/> 10% Owner ____ Officer (give title below) ____ Other (specify below)	
(Last) C/O 1000 SKOKIE BLVD, STE 350,	(First) 	(Middle) 	3. Date of Earliest Transaction (Month/Day/Year) 12/18/2019		
(Street) WILMETTE, IL 60091			4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) ____ Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned		

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common stock	12/18/2019		P		125,000	A	\$ 8	291,667	D (1)	
Common stock								4,111,272.88	I	See Footnotes (1) and (2) (1) (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Tactic Pharma LLC C/O 1000 SKOKIE BLVD, STE 350 WILMETTE, IL 60091		X		
Mazar Andrew Paul 1000 SKOKIE BLVD, STE 350 WILMETTE, IL 60091	X	X	Chief Scientific Officer	
Robinson Chandler 1000 SKOKIE BLVD, STE 350 WILMETTE, IL 60091	X	X	Chief Executive Officer	

O'Halloran Thomas V. 1000 SKOKIE BLVD., STE 350 WILMETTE, IL 60091		X		
Brown Michael J C/O EURONET WORLDWIDE, INC. 3500 COLLEGE BLVD LEAWOOD, KS 66211	X	X		

Signatures

/s/ Kim R. Tsuchimoto, Attorney-in-fact <small>**Signature of Reporting Person</small>		12/20/2019 <small>Date</small>
/s/ Kim R. Tsuchimoto, Attorney-in-fact <small>**Signature of Reporting Person</small>		12/20/2019 <small>Date</small>
/s/Kim R. Tsuchimoto, Attorney-in-fact <small>**Signature of Reporting Person</small>		12/20/2019 <small>Date</small>
/s/Kim R. Tsuchimoto, Attorney-in-fact <small>**Signature of Reporting Person</small>		12/20/2019 <small>Date</small>
/s/ Kim R. Tsuchimoto, Attorney-In-Fact <small>**Signature of Reporting Person</small>		12/20/2019 <small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, (1) Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein.

(2) Tactic has voting and investment power over 4,111,272.88 of the shares of common stock held by TacticGem LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.